Merck, Schering-Plough Dodge Vytorin Enforcement Bullet
This article was originally published in The Pink Sheet Daily
Executive Summary
In settlement with state attorneys general, the companies agree to pay $5.4 million to cover investigative costs and recommit to routine oversight policies.
You may also be interested in...
Merck’s Vytorin Litigation Saga Ends With $688 Million Securities Class Action Settlements
Investors alleged they lost money from the nearly two-year delay in release of results of the Enhance trial; Merck and Schering previously paid $5.4 million to states to resolve Enhance investigation.
FDA's DTC Review Problems Highlight Industry's Growing Legal Squeeze
The Government Accountability Office's report on FDA's staffing and budgeting problems highlights the agency's funding challenge: it's so strapped that it often can't even effectively assess how it's using its resources
FDA's DTC Review Problems Highlight Industry's Growing Legal Squeeze
The Government Accountability Office's report on FDA's staffing and budgeting problems highlights the agency's funding challenge: it's so strapped that it often can't even effectively assess how it's using its resources